MedPath

Effect of Shampakadi Kwatha in the management of Vatrakta w.s.r to Hyperuricemia

Phase 4
Conditions
Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseasesHealth Condition 2: E790- Hyperuricemia without signs of inflammatory arthritis and tophaceous disease
Registration Number
CTRI/2023/01/049163
Lead Sponsor
Principal
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1) Patients of either gender in the age group between 20-70 years.

2) Patients having serum uric acid level level more than 7mg/dl (male) and more than 6mg/dl (female) with or without any associated features of joint inflammation.

Exclusion Criteria

1) Patient not willing for the trial.

2) Patient below age of 20 years and above 70 years of age.

3) Patient suffering from any other form of arthritis like osteoarthritis, Tubercular arthritis, Rheumatoid etc.

4) Patient suffering from chronic renal, respiratory, cardiac and hepatic disorders.

5)Patient having malignant disorder.

6) Patients who has completed participation in any other clinical trial during the past 3 months.

7) Any condition which the investigator thinks may comprise with the safety of the subject.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate the clinical efficacy of Shampakadi Kwatha in the management of Vatarakta w.s.r. to Hyperuricemia. <br/ ><br>Relief in symptoms of Vatrkata after intervention of Shampakadi kwatha <br/ ><br>Sandhishoola-joint pain <br/ ><br>Sandhishotha-Sweling of the joint <br/ ><br>Raga/Redness <br/ ><br>Twakavaivarnya/discoloration of skin <br/ ><br>Sparasashyata/tenderness <br/ ><br>Vidaha- Burning sensation <br/ ><br>Timepoint: Duration of trial : 6 weeks <br/ ><br>Follow up : After every 2 weeks till the completion of trial <br/ ><br>Dosage : Shampakadi kwatha â?? 50 ml Twice a day <br/ ><br>Route of administration : Oral <br/ ><br> <br/ ><br> <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
To assess the clinical safety and adverse effects of Shampakadi Kwath. Improving quality of lifeTimepoint: At the 4weeks, 6 weeks and remain connected with telephonically to know the A.D.Rs if there is any after completion of trial
© Copyright 2025. All Rights Reserved by MedPath